Cargando…

Heteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central India

BACKGROUND & OBJECTIVES: A combination of resistant and susceptible Mycobacterium tuberculosis (MTB) isolated from clinical specimens is referred to as heteroresistance. Heteroresistance leads to difficulties in drug resistance testing and may adversely affect treatment outcomes. The present stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desikan, Prabha, Panwalkar, Nikita, Punde, Ram Prakash, Khan, Zeba, Pauranik, Ankur, Mirza, Shaina Beg, Chourey, Manju, Anand, Sridhar, Sachdeva, K.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Practice: Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319389/ https://www.ncbi.nlm.nih.gov/pubmed/37202936 http://dx.doi.org/10.4103/ijmr.ijmr_607_22

Ejemplares similares

Line probe assay for detection of Mycobacterium tuberculosis complex: An experience from Central India
por: Desikan, Prabha, et al.
Publicado: (2017)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Genetic diversity of Mycobacterium tuberculosis isolates from central India
por: Desikan, Prabha, et al.
Publicado: (2016)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats
por: Sankar, M., et al.
Publicado: (2015)

Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium Tuberculosis by Droplet Digital PCR
por: Zheng, Yang, et al.
Publicado: (2022)

Sero-Occurrence of HBV/HCV Co-infection and Levels of Liver Enzymes among Patients at a Tertiary Care Hospital in Central India: a Pilot Study
por: Desikan, Prabha, et al.
Publicado: (2019)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

Genotypic and phenotypic drug-resistance detection and prevalence of heteroresistance in patients with isoniazid- and multidrug-resistant tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats
por: Ambrose, Samuel Stephen, et al.
Publicado: (2013)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
por: Brewer, Christopher Trent, et al.
Publicado: (2020)

Rifampicin-Resistant Mycobacterium tuberculosis Among Patients with Presumptive Tuberculosis in Addis Ababa, Ethiopia
por: Araya, Shambel, et al.
Publicado: (2020)

Trends in rifampicin resistance among patients with presumptive TB in the pre-COVID and COVID-era
por: Alao, Michael Abel, et al.
Publicado: (2022)

Trends in Rifampicin Resistance Among Children With Presumptive TB in the Pre-COVID and COVID-Era
por: Alao, Michael Abel, et al.
Publicado: (2023)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Development and In Vitro Release of Isoniazid and Rifampicin-Loaded Bovine Serum Albumin Nanoparticles
por: Ge, Zhaohui, et al.
Publicado: (2018)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism
por: Biswas, Ayan, et al.
Publicado: (2020)

Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media
por: Mwila, Chiluba, et al.
Publicado: (2020)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

INCIDENCE OF RIFAMPICIN-RESISTANCE PRESUMPTIVE M. TUBERCULOSIS CASES AMONG OUTPATIENTS IN KEBBI STATE, NIGERIA
por: Danlami, Mohammed Bashar, et al.
Publicado: (2020)

Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016
por: Tamilzhalagan, Sembulingam, et al.
Publicado: (2021)

Hepatoprotective activity of Ficus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity
por: Parameswari, Sundaramoorthi Angala, et al.
Publicado: (2013)

Evaluation of Biochip System in Determining Isoniazid and Rifampicin Resistances of Mycobacterium Tuberculosis in Sputum Samples
por: Lu, Wei, et al.
Publicado: (2012)

Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis
por: Cilfone, NA, et al.
Publicado: (2015)

Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR
por: Sahebi, Leyla, et al.
Publicado: (2016)

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India
por: Munir, Asma, et al.
Publicado: (2019)

Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid
por: Tang, Peijun, et al.
Publicado: (2017)

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates
por: Muthaiah, Muthuraj, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_genqneitgic6forhdvdopvjlk2